Table 1.
Baseline characteristics of patients and controls
| PsA axial (n = 12) | PsA peripheral (n = 28) | Osteoarthritis (n = 10) | Controls (n = 20) | |
|---|---|---|---|---|
| Age, mean (range) years | 32 (24–61) | 27 (20–57) | 46 (32–69) | 34 (28–69) |
| Sex, no. (%) female | 6 (50) | 12 (43) | 7 (70) | 14 (70) |
| HLA‐B27 (%) | 3 | 5 | 0 | – |
| Disease duration, mean (range) months | 52 (10–65) | 40 (10–64) | 33 (11–140) | – |
| CRP (mg/l), mean (range) | 3.7 (1.6–5) | 4.5 (3–12) | 2 (1.5–3) | – |
| DAPSA score, mean (range) | – | 5.7 (3.6–10) | – | – |
| BASDAI score, mean (range) | 5.2 (4–7) | – | – | – |
| Salazopyrin (%) | – | 7 (25) | – | – |
| Methotrexate (%) | – | 7 (25) | – | – |
| Adalimumab (%) | 8 (66) | 18 (64) | – | – |
| Ustekinumab (%) | 4 (34) | 10 (36) | – | – |
PsA = psoriatic arthritis; HLA = human leucocyte antigen; CRP = C‐reactive protein; DAPSA = Disease Activity Index for Psoriatic Arthritis; BASDAI = Bath Ankylosing Spondylitis Disease Activity index.